Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bio-Path Holdings, Inc. - Common Stock (NQ: BPTH )

0.2100 UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bio-Path Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
US Stocks Edge Higher; PepsiCo Cuts 2024 Revenue Outlook
Via Benzinga
ACHR, BPTH, PLUG, REGRF:
Leaders Report Latest Advances 
Via News Direct
Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer
Bio-Path is advancing its obesity treatment BP1001-A and completing trials for BP1002 in acute myeloid leukemia, targeting resistance mechanisms in treatment. Preclinical studies for obesity are set... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Bio-Path Holdings Announces Publication in Biomedicines
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 24
Dallas, Texas--(Newsfile Corp. - September 4, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path... 
Via Newsfile
Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Bio-Path Holdings, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
What Happened With Bio-Path Stock Today?
Bio-Path shares ended Wednesday's session slightly higher after the company provided an update from its ongoing Phase 1/1b clinical trial of BP1001-A. 
Via Benzinga
Bio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A’s Compelling Potential as Treatment for Advanced Solid Tumors
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Reports Second Quarter 2024 Financial Results
Conference Call to be Held Today at 8:30 A.M. ET 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
BPTH Stock Earnings: Bio-Path Holdings Beats EPS for Q2 2024
BPTH stock results show that Bio-Path Holdings beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Bio-Path Holdings to Announce Second Quarter 2024 Financial Results on August 15, 2024
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Provides Clinical Update and Expansion Plans
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Tuesday morning! 
Via InvestorPlace
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Onsemi Layoffs 2024: What to Know as Onsemi Cuts 1,000 Jobs
Onsemi layoffs are a hot topic on Friday after the company announced plans to cut jobs and close down some of its sites on weak demand. 
Via InvestorPlace
Topics Workforce
Exposures Layoff
Why Bank of America Thinks Hasbro (HAS) Stock Can Gain 40% From Here
Hasbro stock is up on Friday with a price target increase and rating upgrade for HAS shares from Bank of America analsyts. 
Via InvestorPlace
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
From FN Media Group LLC
Via GlobeNewswire
Why Is Bio-Path (BPTH) Stock Up 20% Today?
Bio-Path stock is up on Friday with heavy trading of NPTH shares after the company posited positive interim data from a Phase 2 study. 
Via InvestorPlace
Why Bio-Path Stock Is Climbing Today
Bio-Path Holdings shares are trading higher Friday after the company announced interim results from its Phase 2 study of prexigebersen in combination with decitabine and venetoclax for the treatment of... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress
Encore Presentation Highlights Positive Results from Interim Analysis Demonstrating Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients 
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 24
Dallas, Texas--(Newsfile Corp. - June 4, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate... 
Via Newsfile
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
From Bio-Path Holdings, Inc.
Via GlobeNewswire
Dow Dips Over 300 Points; GameStop Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.